New study reveals how long patients stay on secukinumab for skin and joint conditions
NCT ID NCT05155098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis who were already taking or starting secukinumab. Researchers observed them for two years to see how long they continued the medication and how their quality of life changed. The goal was to gather real-world data on treatment patterns and effectiveness outside of a controlled clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
secukinumab
What this could lead to
If successful, this study could show how well secukinumab works in everyday practice, helping doctors and patients make more informed treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or lifestyle. It does not test a new treatment or prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Songkhla, Hat Yai, 90110, Thailand
-
Novartis Investigative Site
Muang, Thailand, 12120, Thailand
-
Novartis Investigative Site
Khon Kaen, THA, 40002, Thailand
-
Novartis Investigative Site
Bangkok, 10300, Thailand
-
Novartis Investigative Site
Bangkok, 10330, Thailand
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Bangkok, 10700, Thailand
-
Novartis Investigative Site
Chiang Mai, 50200, Thailand
-
Novartis Investigative Site
Kaen, 40000, Thailand
-
Novartis Investigative Site
Nakhon Ratchasima, 30000, Thailand